Tissue-advanced glycation end product concentration in dialysis patients. - Wikidata - awgldk - TriplyDB

Tissue-advanced glycation end product concentration in dialysis patients.

Tissue-advanced glycation end product concentration in dialysis patients.

http://www.wikidata.org/entity/Q33571288

about

Elevated levels of procoagulant plasma microvesicles in dialysis patients.Skin autofluorescence as a novel marker of vascular damage in children and adolescents with chronic kidney disease The Association between Polyclonal Combined Serum Free Light Chain Concentration and Mortality in Individuals with Early Chronic Kidney Disease.Skin autofluorescence and the association with renal and cardiovascular risk factors in chronic kidney disease stage 3.Comparison of risk factors for cardiovascular disease in hemodialysis and peritoneal dialysis patients.Skin autofluorescence as a marker of cardiovascular risk in children with chronic kidney disease."NEPP" peritoneal dialysis regimen has beneficial effects on plasma CEL and 3-DG, but not pentosidine, CML, and MGO.Uremic Toxicity of Advanced Glycation End Products in CKD.Skin Autofluorescence and Mortality in Patients on Peritoneal Dialysis.Reducing cardiometabolic risk in peritoneal dialysis patients: role of the dialysis solution Diabetic muscle infarction: a rare cause of acute limb pain in dialysis patients.Skin advanced glycation end-products evaluation in infants according to the type of feeding and mother's smoking habits.Vascular effects of advanced glycation endproducts: Clinical effects and molecular mechanisms Peritoneal changes in patients on long-term peritoneal dialysis.Tissue advanced glycation end products (AGEs), measured by skin autofluorescence, predict mortality in peritoneal dialysis.Skin autofluorescence advanced glycosylation end products as an independent predictor of mortality in high flux haemodialysis and haemodialysis patients.Sudden Death in End Stage Renal Disease: Comparing Hemodialysis versus Peritoneal Dialysis.Tissue advanced glycation end product deposition after kidney transplantation.Advanced glycation end products, aortic stiffness, and wave reflection in peritoneal dialysis as compared to hemodialysis.

P2860

Q34927281-CEF5DC6E-037B-4785-A43F-74601D3BE2BD Q35214629-CA038597-76DE-4A2B-8BA2-30845363CC67 Q35680192-1FFE6576-284B-42F8-A4A1-5A71C50ADE5A Q35985860-A1CC5E8E-3CBF-404E-A948-5BADF2B80151 Q36019451-8E5CCA67-448B-4CD4-8C0C-F62F2B5517E8 Q36420791-66CD00CE-04E2-4032-8762-8D34DCB04E5A Q36475512-3C29A538-142B-42B6-9F33-948D319966BF Q36514906-2F5B54A9-91BB-42A9-AC77-E5C526D6B596 Q37016642-AF3E0292-63F6-4DDE-A97E-AF148A286AF3 Q37453147-D560FF89-2D92-441F-97CC-B67F1A939DB0 Q37556253-2206E00C-F6CB-402A-A53F-F73E979D6795 Q37635808-71E381E5-884D-4840-8F57-C66A73977BB6 Q37636453-B874C746-22F5-4C64-A65F-9BCBE8E298C6 Q38106610-21CA4DEC-444E-48C0-A776-25325BD62D82 Q39094081-1D891AE8-F1EA-4BF6-A7BF-B60B95A91462 Q41715138-B7D71C57-5E19-44D6-BA29-93C966C83E26 Q50758909-1C4E7D4C-95DE-4361-9435-832CF64CE5E4 Q53731078-222EC687-83C1-4F76-ABDF-7FD235714D31 Q54586730-C380323B-53E0-407A-A5A5-314D757BD600

P2860

Tissue-advanced glycation end product concentration in dialysis patients.

http://www.wikidata.org/entity/Q33571288

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Tissue-advanced glycation end product concentration in dialysis patients.

@ast

Tissue-advanced glycation end product concentration in dialysis patients.

@en

Tissue-advanced glycation end product concentration in dialysis patients.

@nl

type

label

Tissue-advanced glycation end product concentration in dialysis patients.

@ast

Tissue-advanced glycation end product concentration in dialysis patients.

@en

Tissue-advanced glycation end product concentration in dialysis patients.

@nl

prefLabel

Tissue-advanced glycation end product concentration in dialysis patients.

@ast

Tissue-advanced glycation end product concentration in dialysis patients.

@en

Tissue-advanced glycation end product concentration in dialysis patients.

@nl

P1433

Q33571288-93A6AA07-AD90-4CCB-BFAA-488BD56B0E98

P1476

Q33571288-D9551820-DC3D-42EE-8D49-372E63046D0A

P2093

Q33571288-35C6F0E3-E141-4E83-8EB9-6225F17564EB

Q33571288-43409C20-320D-49D5-9516-E9C748DFDA84

Q33571288-9400C6E6-432C-416D-A1DA-8F1FE86E1DE7

Q33571288-D89FBC24-43FD-4E2A-A6F9-7C9D57D895E0

Q33571288-EA1CBA1B-6905-4E23-AE07-964EC23A3142

Q33571288-FD874C48-52AD-43DE-B398-C09B4923EB23

P2860

Q33571288-0D28337C-FA9F-420A-8D99-88EE888C1E93

Q33571288-173D94DB-ECF6-4AE3-8CF9-EE527A75EC4B

Q33571288-2357A454-4EBD-4EF7-8816-9DFE07346BDB

Q33571288-2C4D6299-D6F6-4C1A-BC68-60DA2297D403

Q33571288-3580814A-715F-49A1-872B-50787B7EC5BC

Q33571288-3AE119D0-75D2-4E46-9579-AC3C1E5A9D96

Q33571288-3D65E269-A94D-435F-9EE3-2F2021519BD0

Q33571288-48E123F6-73C8-4049-8D8D-3CEE999B2EF0

Q33571288-4AD2BF6C-9411-4D87-8D66-5D0E4FF0E35F

Q33571288-4EDF894C-EE2D-4AE6-99BC-B0CE4EA00C59

P304

Q33571288-42B260CD-4FA8-42C3-83B3-121115F4A93A

P31

Q33571288-C058ECEF-988F-478C-8CE7-A892EAF0DD31

P356

Q33571288-A0FB0387-9A49-4A8A-BEF6-DF1668932F5D

P433

Q33571288-1684E2E2-E723-412B-B04B-E28C837C984B

P478

Q33571288-FD4F44F0-1797-4CD5-A766-33C9F142D4CC

P50

Q33571288-23E1B5FB-E70C-4F6C-BA7D-C435EE10D57D

Q33571288-64D0B62D-AC5A-46E1-A72B-A7D1F3EAFB77

P577

Q33571288-86DB47EB-A49C-4756-8C13-213EC664F60B

P698

Q33571288-11883B5F-2737-4377-A4B1-6FEBE133C2C6

P921

Q33571288-5D64DC41-6CDD-4A3E-9997-454ECC196B75

P932

Q33571288-C0D00732-EAA4-4C2C-B8A3-F8AF11D3682C

P356

P1433

Clinical Journal of the American Society of Nephrology

P1476

Tissue-advanced glycation end product concentration in dialysis patients.

@en

P2093

Christopher W McIntyre

http://www.w3.org/2001/XMLSchema#string

Helen J Jefferies

http://www.w3.org/2001/XMLSchema#string

Lindsay J Chesterton

http://www.w3.org/2001/XMLSchema#string

Natasha J McIntyre

http://www.w3.org/2001/XMLSchema#string

Richard J Fluck

http://www.w3.org/2001/XMLSchema#string

Stephen G John

http://www.w3.org/2001/XMLSchema#string

P2860

Simple non-invasive assessment of advanced glycation endproduct accumulation

Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage

Chemistry of glucose and biochemical pathways of biological interest.

Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management.

Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond.

From life to death--the struggle between chemistry and biology during aging: the Maillard reaction as an amplifier of genomic damage.

Therapeutic potential of AGE inhibitors and breakers of AGE protein cross-links.

Receptor for advanced glycation endproducts (RAGE) and vascular inflammation: insights into the pathogenesis of macrovascular complications in diabetes.

Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults.

Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes.

P304

51-55

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2215/CJN.05350709

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

James O. Burton

P577

2009-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19965551

http://www.w3.org/2001/XMLSchema#string

P921

P932

2801641

http://www.w3.org/2001/XMLSchema#string